| LP422816-1 | MDS v3.0 - RAI v1.17.2 - Delirium | COMPONENT | 1 |
| LP422817-9 | MDS v3.0 - RAI v1.17.2 - Hearing, speech, and vision - NC, NP, NQ, SP | COMPONENT | 1 |
| LP422818-7 | MDS v3.0 - RAI v1.16.1 - Staff assessment for mental status | COMPONENT | 1 |
| LP422822-9 | CT global noise | COMPONENT | 1 |
| LP422823-7 | CT size-adjusted dose | COMPONENT | 1 |
| LP422824-5 | CT dose and image quality category | COMPONENT | 1 |
| LP422825-2 | CT quality measure out of range | COMPONENT | 1 |
| LP422826-0 | Average diameter on axial mid-scan image | COMPONENT | 1 |
| LP422827-8 | Average diameter on frontal scout image | COMPONENT | 1 |
| LP422831-0 | MDS v3.0 - RAI v1.17.2 - Cognitive patterns - ND, SD | COMPONENT | 1 |
| LP422832-8 | Date referral lab test results received | COMPONENT | 1 |
| LP422833-6 | Referral lab test panel | COMPONENT | 1 |
| LP422834-4 | Sub-maximal exercise stress test study | COMPONENT | 1 |
| LP422835-1 | Referral lab test results | COMPONENT | 1 |
| LP422836-9 | Referral lab test name | COMPONENT | 1 |
| LP422837-7 | Referral lab test method | COMPONENT | 1 |
| LP422838-5 | Referral lab test reference range | COMPONENT | 1 |
| LP422839-3 | Referral lab test identifier and name | COMPONENT | 1 |
| LP422840-1 | Referral lab test identifier | COMPONENT | 1 |
| LP422841-9 | Spine Tango | METHOD | 9 |
| LP422842-7 | Received scheduled pain medication regimen | COMPONENT | 1 |
| LP422843-5 | Received PRN pain medications or was offered and declined | COMPONENT | 1 |
| LP422844-3 | Received non-medication intervention for pain | COMPONENT | 1 |
| LP422845-0 | Limited activities because of pain | COMPONENT | 1 |
| LP422849-2 | Date referral lab test sent | COMPONENT | 1 |
| LP422860-9 | Exercise stress test study | COMPONENT | 1 |
| LP422870-8 | Total doses distributed per 100,000 population | COMPONENT | |
| LP422871-6 | Vaccine doses distributed | COMPONENT | 1 |
| LP422872-4 | People who have received first dose of vaccine | COMPONENT | 1 |
| LP422873-2 | People who are fully vaccinated | COMPONENT | 1 |
| LP422874-0 | Vaccine doses distributed for use in long term care facilities | COMPONENT | 1 |
| LP422875-7 | People in long-term care facilities who have received first dose of vaccine | COMPONENT | 1 |
| LP422877-3 | Mass vaccination status | COMPONENT | 1 |
| LP422878-1 | Federal agency code | COMPONENT | 1 |
| LP422879-9 | People in long-term care facilities who are fully vaccinated | COMPONENT | 1 |
| LP422880-7 | Vaccine administered (CVX) code | COMPONENT | 1 |
| LP422881-5 | Vaccine manufacturer (MVX) code | COMPONENT | 1 |
| LP422882-3 | SARS-CoV-2 (COVID-19) M gene | COMPONENT | 1 |
| LP422883-1 | Magnesium and phosphate and lactate panel | COMPONENT | 1 |
| LP422889-8 | Spine Tango surgery follow-up 2017 | COMPONENT | 1 |
| LP422890-6 | Follow-up | COMPONENT | |
| LP422892-2 | Level of spine intervention | COMPONENT | 1 |
| LP422893-0 | Postoperative follow-up interval | COMPONENT | 1 |
| LP422894-8 | Postoperative work status | COMPONENT | 1 |
| LP422895-5 | Postoperative therapeutic goals or measures that were achieved | COMPONENT | 1 |
| LP422896-3 | Postoperative therapeutic goals or measures that were partially achieved | COMPONENT | 1 |
| LP422897-1 | Postoperative therapeutic goals or measures that were not achieved | COMPONENT | 1 |
| LP422898-9 | Medication for spinal surgery or pathology | COMPONENT | 1 |
| LP422899-7 | Postoperative rehabilitation | COMPONENT | 1 |
| LP422900-3 | Overall outcome of spine surgery | COMPONENT | 1 |